Companies ›Basic Materials ›KBLB.PK

KBLB.PK — OTC Diversified Specialty Chemicals

Kraig Biocraft Laboratories Inc

$0,10

Open in Charts → Attach watcher ⌖

— —

USD

Set alert

Last 30 days

1D5D1M3M6MYTD1Y5YMax

Live price chart loads from the market-data widget.

Mcap

—

P/E

—

EV / Rev

—

Div yield

—

Op margin

—

ROE

45,3 %

Net margin

—

Debt / equity

-0,19

Beta

—

52w range

—

Volume

—

Day range

—

Prev close

—

Open

—

Next earnings

2026-10-28

Ex-dividend

—

TR 1Y

—

About

Kraig Biocraft Laboratories Inc is a specialty chemicals company focused on the development and commercialization of high-performance spider silk-based fibers and materials.

Business. Kraig Biocraft Laboratories Inc (KBLB.PK) is a diversified specialty chemicals company operating within the Basic Materials sector. The firm is headquartered in the United States and is primarily listed on the OTC market. Specific details regarding its operating segments and geographic revenue mix are not available.

Classification99 %

SectorBasic Materials

Industry groupDiversified Specialty Chemicals

Generated · model-assisted

Sell-side consensus

—consensus pending

— buy— hold— sell

Avg 12m price target—

Upcoming events

EarningsQ3 2026 earnings (expected)2026-10-28 · estimated

See all catalysts →

At a glance

Score

—

not yet scored

Valuation

—

valuation pending

Analysts

—

not yet wired

Ownership

—

not yet wired

Profitability→

45,3 %

return on equity

Quality

—

not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

No recent newsroom coverage mentioning KBLB.

Sector rotation

Sector1D1Mvs mkt

Materials · THIS SECTOR+2,3 %+6,6 %+1,7 %

Communication Services+2,2 %−5,5 %+1,6 %

Energy+0,6 %+3,3 %+0,0 %

Health Care+0,6 %−0,8 %+0,0 %

Information Technology+0,6 %+6,7 %+0,0 %

Consumer Discretionary+0,4 %+7,6 %−0,2 %

Financials−0,3 %−2,8 %−0,9 %

Consumer Staples−0,4 %+2,5 %−1,0 %

Real Estate−0,7 %+10,9 %−1,3 %

Industrials−1,9 %−3,1 %−2,5 %

Utilities−1,9 %+28,2 %−2,5 %

Developing storylines

No tracked sagas currently linked to KBLB.PK. Browse all sagas →

Analysis

AI analysis

Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

Opportunity

— missing data

Upcoming catalysts

Scheduled public events. Informational only — not investment advice.

Company
EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
Macro
Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
Macro & political
ElectionSE Swedish Election2026-09-14 · SE
ElectionUS U.S. Midterms2026-11-03 · US
ElectionFR French Legislative2027-06-01 · FR

Pre-earnings brief

— missing data

Signals & dispatch

peak dispatch · —

Composite-score breakdown

Synthesis

Business

Kraig Biocraft Laboratories Inc (KBLB.PK) is a diversified specialty chemicals company operating within the Basic Materials sector. The firm is headquartered in the United States and is primarily listed on the OTC market. Specific details regarding its operating segments and geographic revenue mix are not available.

Classification99 %

SectorBasic Materials

Industry groupDiversified Specialty Chemicals

AI synthesis

GENERATED

Kraig Biocraft Laboratories Inc has a negative equity position of -$7.999 million and a debt-to-equity ratio of -0.19, indicating a capital structure heavily reliant on debt and negative equity. The company's liquidity is constrained, with a current ratio of 0.18, suggesting limited ability to meet short-term obligations. Free cash flow is negative at -$3.604 million, and operating cash flow is -$1.789 million, reflecting ongoing cash outflows from operations.

Profitability metrics are weak, with a return on equity of 0.453 and a return on assets of -1.4123. These figures are below typical thresholds for healthy performance in the specialty chemicals industry, where return on equity and return on assets are key indicators of operational efficiency and capital utilization.

The company's revenue is reported at $0, indicating no current revenue generation. There is no disclosed segment or geographic breakdown of revenue, as the company is not generating revenue at this time. This lack of revenue concentration data suggests the company is in an early or development phase.

The company's growth trajectory is not quantifiable due to the absence of historical revenue data and the current zero revenue figure. The outlook for the current fiscal year and the next fiscal year is not provided, but the company's financial position suggests a need for significant capital or revenue generation to sustain operations.

The company faces medium liquidity risk and low dilution risk. The negative net cash position after subtracting total debt is a key flag, indicating potential challenges in maintaining liquidity. No dilution adjustments have been applied, and the company's equity position is negative, which may limit its ability to raise additional capital through equity issuance.

Recent events include the company's ongoing operations in the development of spider silk-based fibers and materials. No specific recent filings or transcripts are provided in the available data, but the company's financial position suggests a focus on research and development rather than commercial operations.

Key takeaways

Kraig Biocraft Laboratories Inc is operating with a negative equity position and significant debt, indicating a high reliance on external financing.
The company is not generating revenue and has negative cash flows from operations, suggesting a need for substantial capital to continue operations.
The company's liquidity position is weak, with a current ratio of 0.18, indicating limited ability to meet short-term obligations.
The company's profitability metrics are poor, with a negative return on assets and a return on equity that is not indicative of a healthy business.
The company's growth trajectory is not quantifiable due to the absence of historical revenue data and the current zero revenue figure.
The company faces medium liquidity risk and low dilution risk, with a negative net cash position after subtracting total debt.

Bull / Bear case

Generated · model-assisted

— missing data

In focus — financials by report

Valuation

Market price

$0,10

Market cap

—

Enterprise valueⓘ

—

P/Eⓘ

—

Non-GAAP P/Eⓘ

—

EV / Revenueⓘ

—

EV / Op incomeⓘ

—

EV / OCFⓘ

—

P / Bⓘ

—

P / Tangible bookⓘ

—

Tangible book

-$8.0M

Net cashⓘ

-$1.5M

Current ratioⓘ

0.2

Debt / equityⓘ

-0.2

ROAⓘ

-1.4%

ROEⓘ

45.3%

Cash conversionⓘ

49.0%

CapEx / revenueⓘ

—

SBC / revenueⓘ

—

Dilution ratioⓘ

0.0%

Revenue by segment

Business relationships

— missing data

Supply chain

— missing data

Peer comparison

Peer comparison8 peers · vs KBLB · multiples and returns

ECL—

Ecolab Inc

$279,43

79,3B USD

P/E

38,5x

— vs self

Div yield

0,9 %

— vs self

ROE

20,8 %

— vs self

CE—

Celanese Corp

$43,89

4,8B USD

P/E

—

— vs self

Div yield

—

— vs self

ROE

-28,7 %

— vs self

EMN—

Eastman Chemical Co

$71,98

8,3B USD

P/E

17,0x

— vs self

Div yield

4,8 %

— vs self

ROE

7,9 %

— vs self

ALB—

Albemarle Corp

$118,71

14,1B USD

P/E

—

— vs self

Div yield

0,8 %

— vs self

ROE

-5,2 %

— vs self

SQM—

SQM

—

P/E

—

— vs self

Div yield

—

— vs self

ROE

—

— vs self

CBT—

Cabot Corp

$89,58

4,7B USD

P/E

14,8x

— vs self

Div yield

1,9 %

— vs self

ROE

21,1 %

— vs self

FUL—

H.B. Fuller Co.

$57,01

3,2B USD

P/E

159,6x

— vs self

Div yield

1,6 %

— vs self

ROE

1,0 %

— vs self

ESI—

Element Solutions Inc

$37,69

9,2B USD

P/E

49,9x

— vs self

Div yield

0,8 %

— vs self

ROE

7,0 %

— vs self

Market position

Stress test

— missing data

Predictor forecast

Options

— missing data

Short squeeze

— missing data

Earnings-call key lines

— missing data

Estimate revisions

consensus EPS · 26-week trend

— missing data

Sell-side observations

— missing data

Themes

— missing data

ESG

— missing data

Risk factors

Dilution riskLow

Liquidity riskMedium

Filing-based flags

Net cash is negative after subtracting total debt.

Benchmarks vs cohort

ROE45,3 %Best in class

D/E-0,19Above P75

Cash Conv0,49Below median

Corporate actions / M&A

— missing data

FX exposure

— missing data

Comparable transactions

— missing data

Derivatives & instruments

— missing data

Actions

Set alert Open in charts

Ask Handelsavisen

— missing data

Data sources

Market data
Market data cache
Issuer disclosures
Public news
Earnings transcripts
Consensus estimates
ESG data

How metrics are computed

Dilution Ratio
(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
Net Cash
cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
Return On Equity
net_income / total_equity
Debt To Equity
(short_term_debt + long_term_debt) / total_equity
Cash Conversion Ratio
operating_cash_flow / net_income
Return On Assets
net_income / total_assets

Source documents

Kraig Biocraft Laboratories Inc Market data — financials · 2026-05-28

Ownership & reference

Insider activity

— missing data

Short positioning

6.9Kshares short-62.8% vs prior

1days to cover

200.1Kfails-to-deliver

as of 2026-06-30 · short-interest report (free)

Geographic breakdown

— missing data

Listings · one canonical issuer all listings resolve to the canonical

KBLB.PKCanonical

OTC · USD

Intel & risk

peak dispatch · —

OSINT findings

Dilution riskLow

Liquidity riskMedium

Net cash is negative after subtracting total debt.

Evidence & claims

From filings & derived data

Total assets (YoY) (2025-12-31 vs 2024-12-31): 70.4%Derived (calculated)
Return on equity (FY 2025-12-31): 45.3%Derived (calculated)
Return on assets (FY 2025-12-31): -141.2%Derived (calculated)
Current ratio (FY 2025-12-31): 0.18xDerived (calculated)
Debt-to-equity (FY 2025-12-31): -1.32xDerived (calculated)
Capex (YoY) (2025-12-31 vs 2024-12-31): 27.2%Derived (calculated)
Net income (YoY) (2025-12-31 vs 2024-12-31): -6.6%Derived (calculated)
Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): 2.7%Derived (calculated)
Operating income (YoY) (2025-12-31 vs 2024-12-31): -9.8%Derived (calculated)
R&D expense (YoY) (2025-12-31 vs 2024-12-31): 0.8%Derived (calculated)
Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): 1.8%Derived (calculated)
Total liabilities (YoY) (2025-12-31 vs 2024-12-31): 9.4%Derived (calculated)
Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): 165.9%Derived (calculated)
Total operating expenses (annual): USD 3.37MSEC XBRL filing
Net income (annual): USD -3.62MSEC XBRL filing
Shareholders' equity (annual): USD -8MSEC XBRL filing
Cash & equivalents (annual): USD 1.79MSEC XBRL filing
Capex (annual): USD 5.39KSEC XBRL filing
Operating income (annual): USD -3.37MSEC XBRL filing
R&D expense (annual): USD 165.76KSEC XBRL filing
EPS (diluted) (annual): USD-PER-SHARES 0SEC XBRL filing
Total assets (annual): USD 2.57MSEC XBRL filing
Current liabilities (annual): USD 10.45MSEC XBRL filing
Total liabilities (annual): USD 10.56MSEC XBRL filing

Showing 24 of 60 surfaced claims.

Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

The Thread

Everything we know, in order

2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date

The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.

Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage

At a glance

What drives this business

News & coverage

Sector rotation

Developing storylines

Analysis

Opportunity

Upcoming catalysts

Pre-earnings brief

Signals & dispatch

Composite-score breakdown

Synthesis

Bull / Bear case

In focus — financials by report

Valuation

Revenue by segment

Market share

Business relationships

Supply chain

Peer comparison

Market position

Stress test

Predictor forecast

Options

Short squeeze

Earnings-call key lines

Estimate revisions

Sell-side observations

Themes

ESG

Risk factors

Benchmarks vs cohort

Corporate actions / M&A

FX exposure

Comparable transactions

Derivatives & instruments

Actions

Ask Handelsavisen

Ownership & reference

Insider activity

Short positioning

Geographic breakdown

Intel & risk

Evidence & claims

The Thread